These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21194606)

  • 1. A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers.
    Chik Z; Basu RC; Pendek R; Lee TC; Mohamed Z
    Clin Ther; 2010 Sep; 32(10):1822-31. PubMed ID: 21194606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
    Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
    Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.
    McIlleron H; Gabriels G; Smith PJ; Fourie PB; Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S329-35; discussion S351-2. PubMed ID: 10593713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
    Zwolska Z; Niemirowska-Mikulska H; Augustynowicz-Kopec E; Walkiewicz R; Stambrowska H; Safianowska A; Grubek-Jaworska H
    Int J Tuberc Lung Dis; 1998 Oct; 2(10):824-30. PubMed ID: 9783530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
    Pillai G; Ellard GA; Smith PJ; Fourie PB
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma pooling to expedite bioequivalence estimation of rifampicin in fixed dose combinations.
    Panchagnula R; Parmar J; Kaur JK; Singh I; Bhade SR
    Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):161-7. PubMed ID: 16810342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality assurance: protocol for assessing the rifampicin bioavailability of combined formulations in healthy volunteers.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S284-5. PubMed ID: 10593705
    [No Abstract]   [Full Text] [Related]  

  • 9. Determination of rifampicin bioequivalence in a three-drug FDC by WHO and indian protocols: effect of sampling schedule and size.
    Agrawal S; Kaur KJ; Singh I; Bhade SR; Kaul CL; Panchagnula R
    Int J Tuberc Lung Dis; 2005 Jan; 9(1):75-80. PubMed ID: 15675554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative bioavailability of two oral formulations of piroxicam 20 mg: a single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Mexican adult volunteers.
    Palma-Aguirre JA; Lopez-Gamboa M; Cariño L; Burke-Fraga V; González-de la Parra M
    Clin Ther; 2010 Feb; 32(2):357-64. PubMed ID: 20206793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, open-label pharmacokinetic comparison of two oral formulations of fluconazole 150 mg in healthy adult volunteers.
    Jovanović D; Kilibarda V; Cirić B; Vucinić S; Srnić D; Vehabović M; Potogija N
    Clin Ther; 2005 Oct; 27(10):1588-95. PubMed ID: 16330294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence study of two pharmaceutical forms of rifampicin capsules in man.
    Chouchane N; Barre J; Toumi A; Tillement JP; Benakis A
    Eur J Drug Metab Pharmacokinet; 1995; 20(4):315-20. PubMed ID: 8983939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma pooling methodology as a faster and cheaper tool to evaluate bioequivalence of rifampicin component of FDCs of antitubercular drugs.
    Panchagnula R; Sharma A; Agrawal S
    Pharmacol Res; 2003 Dec; 48(6):655-63. PubMed ID: 14527833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma pooling: utility in expediting bioequivalence assessment of rifampicin-containing fixed-dose combinations.
    Ashokraj Y; Singh I; Kaur KJ; Kohli G; Bhade SR; Varma MV; Kaul CL; Panchagnula R
    Int J Tuberc Lung Dis; 2005 Jun; 9(6):697-9. PubMed ID: 15971401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers.
    Pargal A; Rani S
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):70-9. PubMed ID: 11263520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.
    Schall R; Müller FO; Duursema L; Groenewoud G; Hundt HK; Middle MV; Mogilnicka EM; Swart KJ
    Arzneimittelforschung; 1995 Nov; 45(11):1236-9. PubMed ID: 8929247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of bioavailability of two brands of rifampicin.
    Rewari S; Rath R; Gupta U
    J Assoc Physicians India; 1998 Aug; 46(8):751. PubMed ID: 11229300
    [No Abstract]   [Full Text] [Related]  

  • 19. Statistical evaluation of physiological variability of rifampicin in fixed dose combinations.
    Panchagnula R; Parmar J; Kaur K; Singh I; Bade SR; Ashokraj Y
    Int J Pharm; 2006 Apr; 313(1-2):5-13. PubMed ID: 16517107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of rifampicin when administered as a fixed-dose combined formulation of four drugs versus separate formulations.
    Panchagnula R; Kaur KJ; Singh I; Kaul CL
    Methods Find Exp Clin Pharmacol; 2000 Nov; 22(9):689-94. PubMed ID: 11294011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.